Glenmede Trust Co. NA maintained its position in shares of Natus Medical Incorporated (NASDAQ:BABY) during the first quarter, Holdings Channel reports. The firm owned 16,777 shares of the medical equipment provider’s stock at the end of the first quarter. Glenmede Trust Co. NA’s holdings in Natus Medical were worth $583,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Natus Medical by 137,510.8% in the first quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock worth $161,874,000 after buying an additional 4,121,198 shares in the last quarter. Columbia Wanger Asset Management LLC raised its position in shares of Natus Medical by 243.6% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock worth $79,686,000 after buying an additional 1,439,382 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Natus Medical by 105.7% in the first quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock worth $70,457,000 after buying an additional 922,268 shares in the last quarter. Epoch Investment Partners Inc. raised its position in shares of Natus Medical by 68.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,110,932 shares of the medical equipment provider’s stock worth $43,604,000 after buying an additional 450,698 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Natus Medical during the fourth quarter worth approximately $11,560,000. 92.47% of the stock is currently owned by institutional investors and hedge funds.
Shares of Natus Medical Incorporated (BABY) opened at 37.55 on Monday. The company has a market cap of $1.22 billion, a P/E ratio of 36.11 and a beta of 0.95. The company’s 50-day moving average price is $35.01 and its 200 day moving average price is $36.69. Natus Medical Incorporated has a 52 week low of $33.15 and a 52 week high of $44.39.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, April 26th. The medical equipment provider reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by $0.03. The business had revenue of $124.70 million for the quarter, compared to analyst estimates of $122.45 million. Natus Medical had a return on equity of 12.70% and a net margin of 8.17%. Natus Medical’s quarterly revenue was up 42.8% compared to the same quarter last year. During the same period last year, the firm earned $0.34 EPS. On average, equities analysts forecast that Natus Medical Incorporated will post $1.70 EPS for the current fiscal year.
BABY has been the topic of a number of analyst reports. TheStreet lowered Natus Medical from a “b” rating to a “c+” rating in a report on Thursday, April 27th. Zacks Investment Research downgraded Natus Medical from a “hold” rating to a “sell” rating in a research note on Friday, April 28th. Benchmark Co. restated a “buy” rating and set a $48.00 target price (down previously from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. Finally, BidaskClub upgraded Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. Natus Medical has an average rating of “Hold” and a consensus target price of $45.00.
In other Natus Medical news, insider James B. Hawkins purchased 4,000 shares of the stock in a transaction on Thursday, June 15th. The shares were purchased at an average price of $33.98 per share, with a total value of $135,920.00. Following the completion of the transaction, the insider now directly owns 578,023 shares in the company, valued at $19,641,221.54. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Doris Engibous sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $32.68, for a total value of $163,400.00. Following the transaction, the director now directly owns 22,650 shares in the company, valued at approximately $740,202. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284911/natus-medical-incorporated-baby-position-maintained-by-glenmede-trust-co-na.html
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.